Immunitybio, Inc. · NASDAQ:IBRX
Immunitybio — LifeSci Advisors Investor Call, May 27, 2020
18 slides from Immunitybio's conference presentation, May 27, 2020
Slide 1: Vaccine and Therapeutic Initiatives for COVID-19: an Investor Call
Vaccine and Therapeutic Initiatives for COVID-19: an Investor Call with Patrick Soon-Shiong, M.D. May 27, 2020 1
Slide 2: General Disclaimer
General Disclaimer Not all product candidates and/or services referenced in these slides are proprietary to NantKwest or ImmunityBio and may be owned or controlled by third parties, including their affiliates. FORWARD-LOOKING STATEMENTS These slides and the accompanying oral presentation contain for
Slide 3: NantKwest & ImmunityBio: Driving to the Memory T Cell
NantKwest & ImmunityBio: Driving to the Memory T Cell CANCER COVID-19 VACCINE Non-Muscle Invasive Bladder Cancer N-803 + BCG • Breakthrough Therapy Designation Status COVID-19 Vaccine • Primary Endpoint Reached Adenovirus (hAd5) N-803 (IL-15) • BLA Filing 2021 • IND Filed Human Adenovirus • Phase Ib
Slide 4: COVID-19: From Prevention to Treatment
COVID-19: From Prevention to Treatment THE NANT SOLUTION Green: Uninfected Yellow: Moderate Symptoms Red: Severe & Critical Vaccine Therapeutic Therapeutic Uninfected State Mild to Moderate State Critical ICU State 2nd Gen hAd5 N-803: IL-15 Off-The-Shelf Bone Marrow Derived Adenovirus Superagonist N
Slide 5: ImmunityBio & NantKwest: Operation Warp Speed
ImmunityBio & NantKwest: Operation Warp Speed 2nd Generation Human Adenovirus (hAd5) • January 2020: SARS-CoV-2 sequence S Protein (Spike) available RBD • Feb 2020: Vaccine design commences RBD S-Fusion • Feb 2020: SARS-CoV-2 spike protein N inserted into hAd5 vector • March 2020: Multiple vaccine c
Slide 6: A Unique Vector: 2nd Generation Human Adenovirus (hAd5)
A Unique Vector: 2nd Generation Human Adenovirus (hAd5) no de A ] an ed m d5 et u el n H A n -D e e ] G 3- e E3 G at -, 2 nd nd -E lls ys e ] at t 2 2b 3- 2b lth Ce d L s e E ui , E 1- ,E a Ly 1- te Q 1- ed A [E [E ly S d s ct n y ll [ E A l d5 fe tio n el ca d 5 d5 cal A In era tio C i A hA eni a d
Slide 7: ImmunityBio Proprietary 2nd Gen Adenovirus Platform Overcoming Ad Immunity
ImmunityBio Proprietary 2nd Gen Adenovirus Platform Overcoming Ad Immunity A Decade of Development History • Adenovirus serotype 5 viral backbone- Medium sized (90-100nm), non-enveloped, icosahedral, ds DNA as a 1st generation • Developed for use in gene therapy applications • ImmunityBio’s 2nd Gen
Slide 8: H1N1 Pandemic - 2009
H1N1 Pandemic - 2009 H1N1 Pandemic - 2009 Cancer – 2009-2013 Finished Dosage Form at Small Scale Manufactured in cGMP Facility April 27, 2020 PM S-WT pA PM S-WT pA PM N pA 2nd Generation hAd5 Human Adenovirus HIV - 2009 COVID-19 Vaccine Non-Replicating Viral Vaccine Multiple Antigens - 2019 ~12kB Ca
Slide 9: ImmunityBio Proprietary 2nd Gen hAd5 Viral Vector with Four Deletions
ImmunityBio Proprietary 2nd Gen hAd5 Viral Vector with Four Deletions to Enable “Immunologically Quiet” Transfection * * 2nd Generation Adeno hAd5 [E1-, E2b- E3-] Vector Adenovirus serotype 5 virus gene carrier with 4 separate deletions within the adenoviral genome: * *ΔpTP * Four Deletions • E1 gen
Slide 10: 1st Generation vs. 2nd Generation hAd5
1st Generation vs. 2nd Generation hAd5 1st Generation Ad 2nd Generation Ad (CanSino, J&J, Oxford) (ImmunityBio / NantKwest) [E1-, E3-] [E1-, E2b-, E3-] no de First Generation 1st Generation Ad5 Ad5 Vector First Generation 1st Generation Ad5 Ad5 Vector A ] an ed m d5 et u el n H A Cargo Cargo en ] -D
Slide 11: Novel "Immunogenically Quiet" 2nd Gen hAd5 Platform
Oct 2019 Novel “Immunogenically Quiet” 2nd Gen hAd5 Platform Reduction of hAd5 Protein Expression Enabling Multiple Doses no de A an Immuno-Suppressed Cancer Patients Receiving 2nd Generation hAd5 Platform um ] H e n ted e G ele ] at nd D E 3- s 2 Ly 3- - d s a lth , E - [E1 A l e n C el St E2b d5 t
Slide 12: 2nd Generation hAd5: Advanced Solid Tumors
2nd Generation hAd5: Advanced Solid Tumors Immuno-Suppressed Cancer Patients Receiving 2nd Generation hAd5 Platform 5/28/20 Confidential – Not For Distribution 12
Slide 13: A Unique Construct: SARS-CoV-2 (COVID-19)
A Unique Construct: SARS-CoV-2 (COVID-19) RBD RBD S-Fusion RBD N Receptor Binding Domain (RBD) Identification of Key Constructs RBD RBD RBD RBD S Protein S-Fusion (Spike) Unique Vector + Unique Construct S2 S1 N Protein N RBD RBD RBD COVID-19 2nd Generation Human Adenovirus hAd5 5/28/20 Confidential
Slide 14: The Importance of RBD for Neutralization
The Importance of RBD for Neutralization COVID-19 Infection of Human Cells RBD to ACE2 Receptor RBD Receptor Binding Domain (RBD) RBD ACE2 ACE2 RBD S1 S2 RBD RBD RBD RBD ACE2 S Protein (Spike) RBD S-Fusion RBD S2 S1 N Protein RBD RBD N RBD ACE2 Identification of Key Constructs ACE2 RBD RBD NANT 2nd
Slide 15: Finished Dosage Form at Small GMP Scale
Finished Dosage Form at Small GMP Scale Manufactured in cGMP Facility April 27, 2020 2nd Gen hAd5 Adenovirus Vaccine Program T Cell Mediated Immunity Humoral Immunity NANT 2nd Generation Human RBD S-Fusion N Adenovirus (hAd5) Vaccine Construct 5/28/20 Confidential – Not For Distribution 15
Slide 16: Key Attributes of ImmunityBio/NantKwest Vaccine Platform
Key Attributes of ImmunityBio/NantKwest Vaccine Platform Position us for Leadership NANT First Adenoviral Vector Delivering S Fusion + RBD + Nucleocapsid (N) Key Attributes 2nd Gen Protein COVID-19 Construct hAd5 Unique Human Adenovirus (E1-, E2b-, E3- Deleted) Vector Human adenovirus vector without
Slide 17: Operation Warp Speed: COVID-19 Vaccine
Operation Warp Speed: COVID-19 Vaccine Accelerating R&D and Manufacturing in Parallel to Achieve >1 Billion Doses Select Candidate R&D, Scale-Up Manufacturing, Clinical Trials Vaccine Available RBD S1 S2 RBD RBD RBD RBD RBD January 2020 March 2020 May 2020 June-July 2020 August 2020 September 2020 J
Slide 18: NantKwest & ImmunityBio Manufacturing, Development and Marketing Partnership
NantKwest & ImmunityBio Manufacturing, Development and Marketing Partnership 2nd Gen hAd5 Adenovirus Vaccine Program T Cell Mediated Immunity Humoral Immunity 5/28/20 Confidential – Not For Distribution 18
ImmunityBio — LifeSci Advisors Investor Call, May 27, 2020 on 6ix